Oncology

Bevacizumab with chemotherapy reduced risk of disease progression by 62% compared with chemotherapy alone.

The FDA today approved a new indication for an oncology drug that significantly reduces ovarian cancer disease progression.

RAND Corporation projects biosimilars to cause an approximately 4% reduction in total US biologic spending from 2014 to 2024.

According to researchers, chemotherapy parity laws ignore the real question of cost versus quality. At the same time, these laws promote anticompetitive practices that affect community oncologists.

Chemotherapy parity laws ignore the real question of cost versus quality. At the same time, they promote anticompetitive practices that affect community oncologists.

Cost of medication causes financial burden for nearly two-thirds of patients.

Researchers determine there may be an opportunity to reduce chemotherapy in pediatric patients with hepatoblastoma.

Investigational medication may lead to a promising future for the treatment of the disease.

The Key to Treatment of Cancer-Related Cough Is Identifying its Underlying Cause

As one of the first areas in the field, nuclear pharmacy is a prototype of specialty pharmacy practice. Specialty Pharmacy Times reviews the history and some of the fundamentals of nuclear pharmacy.

Ramucirumab approved as a single-agent treatment and in combination with chemotherapy.

Treatment developed by Amgen fails to demonstrate statistically significant improvement in overall survival.

Dispensing generic hormonal therapies instead of their brand-name counterparts increases breast cancer patients' life-saving medication adherence by 50%.

The CHEST Foundation recently launched its Lung Cancer Care: A Team Approach campaign as part of National Lung Cancer Awareness Month. The campaign aims to raise awareness about low treatment rates and the importance of medical specialists working together to provide optimal lung cancer care.

Patients with early stage tumors fare worse with erlotinib than if they take nothing.

Bortezomib found to effectively treat chronic graft-versus-host disease.

Accelerated approval for pembrolizumab based on tumor response rate and durability of response.

The FDA today granted breakthrough therapy designation to a new treatment for non-small cell lung cancer patients.

Nanotechnology and shortwave infrared light reveals small tumors and cardiovascular lesions deep inside body.

Researchers found significant improvements in overall survival and in disease-free survival in patients who received trastuzumab in addition to chemotherapy.

Cyramza (ramucirumab) was approved for treatment of patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma after disease progression.

Adults aged 50 years or older who feel comfortable about aging are more likely to seek preventive health care services.

In the pediatric hospital setting, pharmacists most frequently perform drug therapy changes on the cancer ward.

Treatment inhibits key process that enables cancer cells to multiply.